Results 11 to 20 of about 4,426 (152)

A Multicenter Prospective Cohort Study on the Use of Weight-Adjusted Dalteparin in Patients Over 90 kg With Acute Cancer-Associated Venous Thromboembolism-The WAVe Study. [PDF]

Am J Hematol
The WAVe stdudy‐ A multicenter prospective cohort study of wieght‐adjusted dalteparin in patients over 90 kg with acute cancer‐associated venous thromboembolism. ABSTRACT Patients with cancer‐associated thrombosis (CAT) are commonly treated with low‐molecular‐weight heparin (LMWH), but whether dose capping is needed in patients over 90 kg is unclear ...
Wang TF, Yeo E, Gross PL, Séguin C, Wu C, Shivakumar S, Mallick R, Delluc A, D'Astous J, Kimpton M, Roberge G, Siegal DM, Tritschler T, Le Gal G, Carrier M.   +14 more
europepmc   +2 more sources

Evaluation of Low-Molecular-Weight Heparin for Treatment of Portal Vein Thrombosis in Liver Cirrhosis Patients

Medicina, 2023
Background and Objectives: Even though low-molecular-weight heparin (LMWH), including dalteparin, has a critical role in portal vein thrombosis (PVT) treatment in liver cirrhosis (LC) patients, the predictive factors and the proper dose of dalteparin for
Ji Min Han, Youngil Koh, Sung Hwan Kim, Sung Yun Suh, Yoon Sook Cho, Jeong-Hoon Lee, Su Jong Yu, Jung-Hwan Yoon, Hye Sun Gwak   +8 more
doaj   +1 more source

Renal function and clinical outcome of patients with cancer-associated venous thromboembolism randomized to receive apixaban or dalteparin. Results from the Caravaggio trial

Haematologica, 2021
The effect of renal impairment (RI) on risk of bleeding and recurrent thrombosis in cancer patients treated with direct oral anticoagulants for venous thromboembolism (VTE) is undefined.
Cecilia Becattini, Rupert Bauersachs, Giorgio Maraziti, Laurent Bertoletti, Alexander Cohen, Jean M. Connors, Dario Manfellotto, Antonio Sanchez, Benjamin Brenner, Giancarlo Agnelli   +9 more
doaj   +1 more source

Direct Oral Anticoagulants in Patients With Active Cancer

JACC. CardioOncology, 2020
Background: Many patients with cancer have a hypercoagulable state and an increased risk of developing venous thromboembolism (VTE), arterial occlusion, and pulmonary emboli.
Jolanda Sabatino, MD, PhD, Salvatore De Rosa, MD, PhD, Alberto Polimeni, MD, PhD, Sabato Sorrentino, MD, PhD, Ciro Indolfi, MD   +4 more
doaj   +1 more source

In vitro Effect of Dalteparin and Argatroban on Hemostasis in Critically Ill Sepsis Patients with New-Onset Thrombocytopenia

TH Open, 2023
Thrombocytopenia is common among critically ill sepsis patients, while they also hold an increased risk for thromboembolic events. Thus, the choice of anticoagulant prophylaxis for this patient population is challenging.
Søren Nygaard, Christine L. Hvas, Anne-Mette Hvas, Kasper Adelborg   +3 more
doaj   +1 more source

Meta regression analysis to indirectly compare dalteparin to enoxaparin for the prevention of venous thromboembolic events following total hip replacement

Thrombosis Journal, 2011
Background Patients undergoing elective total hip replacement (THR) surgery are at an increased risk for venous thromboembolic events (VTEs). Dalteparin and enoxaparin are recommended as thromboprophylaxis for at least 10 days in these patients.
Choe Yoonhee, Jelincic Valentina, Dranitsaris George   +2 more
doaj   +1 more source

Enoxaparin versus dalteparin or tinzaparin in patients with cancer and venous thromboembolism: The RIETECAT study

Research and Practice in Thrombosis and Haemostasis, 2022
Background Venous thromboembolism (VTE) is a frequent complication in patients with cancer and a leading cause of morbidity and death. Objectives The objective of the RIETECAT study was to compare the long‐term effectiveness and safety of enoxaparin ...
Javier Trujillo‐Santos, Dominique Farge‐Bancel, José María Pedrajas, Covadonga Gómez‐Cuervo, Aitor Ballaz, Andrei Braester, Isabelle Mahé, Aurora Villalobos, José Antonio Porras, Manuel Monreal, The RIETE Investigators   +10 more
doaj   +1 more source

Apixaban role in the treatment of venous thromboembolic complications in patients with active cancer

Атеротромбоз, 2020
The relationship of venous thromboembolic complications (VTEC) to cancer is well known. Modern recommendations for the treatment of VTEC in patients with cancer suggest treatment with subcutaneous injections of LMWH in the first 6 months.
E. P. Panchenko
doaj   +1 more source

An Adjustable Dalteparin Sodium Dose Regimen for the Prevention of Clotting in the Extracorporeal Circuit in Hemodialysis: A Clinical Trial of Safety and Efficacy (the PARROT Study)

Canadian Journal of Kidney Health and Disease, 2018
Background: Dalteparin sodium, a low-molecular-weight heparin, is indicated for prevention of clotting in the extracorporeal circuit during hemodialysis (HD).
Steven Soroka, Mohsen Agharazii, Sandra Donnelly, Louise Roy, Norman Muirhead, Serge Cournoyer, Martin MacKinnon, Neesh Pannu, Brendan Barrett, François Madore, Karthik Tennankore, Jo-Anne Wilson, Fiona Hilton, Nancy Sherman, Kevin Wolter, John Orazem, Guillaume Feugère   +16 more
doaj   +1 more source

Cost-effectiveness analysis and budget impact of rivaroxaban compared with dalteparin in patients with cancer at risk of recurrent venous thromboembolism

BMJ Open, 2020
Objectives In the ‘Comparison of an Oral Factor Xa Inhibitor With Low Molecular Weight Heparin in Patients With Cancer With Venous Thromboembolism’ (SELECT-D) trial, rivaroxaban showed relatively low venous thromboembolism (VTE) recurrence but higher ...
Maarten J Postma, Lisa A de Jong, Annette W G van der Velden, Marinus van Hulst   +3 more
doaj   +1 more source